altérations cognitives; interventions pharmacologiques; revalidation; cancer
Résumé :
[fr] Objectif. Diverses études rapportent la présence
d’altérations cognitives chez les patients atteints d’un
cancer. Le but de cet article est de proposer une revue
des études longitudinales contrôlées ayant évalué l’efficacité
d’interventions visant à prendre en charge ces altérations cognitives.
Méthode. Les études longitudinales contrôlées ayant
évalué l’efficacité d’interventions visant à prendre en charge
les altérations cognitives chez les patients adultes atteints d’un
cancer et publiées entre 1993 et 2013 ont été identifiées,
à l’exception des études impliquant des patients atteints de
tumeurs ou de métastases cérébrales. Résultats. Parmi les
interventions pharmacologiques (n = 11), certaines suggèrent
l’impact positif du modafinil notamment au niveau mnésique
et exécutif. Les interventions non pharmacologiques
(n = 10) démontrent l’impact positif de programmes de revalidation
cognitive et de stimulation, de psycho-éducation
et de la méditation sur plusieurs fonctions mnésiques,
attentionnelles et exécutives, objectives et subjectives. Les
interventions non pharmacologiques entraînent des améliorations
cognitives plus importantes que les interventions
pharmacologiques. Conclusions. Certaines études longitudinales
contrôlées semblent démontrer l’intérêt de prendre en
charge les altérations cognitives observées chez les patients
atteints d’un cancer. De nouvelles études évaluant l’efficacité
d’interventions combinant prise en charge des altérations
cognitives et soutien psychothérapeutique à l’adaptation psychologique
des patients devraient être menées.
Disciplines :
Traitement & psychologie clinique
Auteur, co-auteur :
Borghgraef, Cindy; Université Libre de Bruxelles - ULB
Libert, Yves; Université Libre de Bruxelles - ULB
Etienne, Anne-Marie ; Université de Liège > Départ. de Psychologies et Cliniques des Systèmes humains > Psychologie de la santé
Delvaux, Nicole; Université Libre de Bruxelles - ULB
Reynaert, Christine; Université Catholique de Louvain - UCL
Razavi, Darius; Université Libre de Bruxelles - ULB
Langue du document :
Français
Titre :
La prise en charge des altérations cognitives en oncologie : une revue des études longitudinales contrôlées
Titre traduit :
[en] Treatment of cognitive impairments in oncology: A review of longitudinal controlled studies
Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T. A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 2013 ; 39 : 297-304.
Hurria A, Somlo G, Ahles T. Renaming "chemobrain". Cancer Invest 2007 ; 25 : 373-7.
Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fog - methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat 2006 ; 95 : 125-9.
Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004 ; 100 : 2292-9.
Bruera E, Miller MJ, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992 ; 48 : 163-6.
Butler JM, Case LD, Atkins J, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2007 ; 69 : 1496-1.
Gehring K, Patwardhan SY, Collins R, et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol 2012 ; 107 : 165-74.
Gehring K, Sitskoorn MM, Gundy CM, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol 2009 ; 27 : 3712-22.
Hulshof MC, Stark NM, van der Kleij A, Sminia P, Smeding HM, Gonzalez Gonzalez D. Hyperbaric oxygen therapy for cognitive disorders after irradiation of the brain. Strahlenther Onkol 2002 ; 178 : 192-8.
Poppelreuter M, Weis J, Mumm A, Orth HB, Bartsch HH. Rehabilitation of therapy-related cognitive deficits in patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008 ; 41 : 79-90.
Chan AS, Cheung MC, Law SC, Chan JH. Phase II study of alpha-tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer 2004 ; 100 : 398-404.
Rapport MD, Denney C, DuPaul GJ, Gardner MJ. Attention deficit disorder and methylphenidate: normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Childadolesc Psychiatry 1994 ; 33 : 882-93.
Jacobsen PB, Garland LL, Booth-Jones M, et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage 2004 ; 28 : 7-18.
Lower EE, Fleishman S, Cooper A, et al. Efficacy of dexmethyl-phenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 2009 ; 38 : 650-62.
Mar Fan HG, Clemons M, Xu W, et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 2008 ; 16 : 577-83.
Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: A pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002 v; 29 : E85-90.
Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008 ; 33 : 1477-502.
Lundorff LE, Jonsson BH, Sjogren P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 2009 ; 23 : 731-8.
Kohli S, Fisher SG, Tra Y, et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 2009 ; 115 : 2605-16.
Hermelink K, Untch M, Lux MP, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007 ; 109 : 1905-13.
Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother 2013 ; 40 : 302-9.
Taxel P, Stevens MC, Trahiotis M, Zimmerman J, Kaplan RF. The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer. J Am Geriatr Soc 2004 ; 52 : 269-73.
Beer TM, Bland LB, Bussiere JR, et al. Testosterone loss and estradiol administration modify memory in men. J Urol 2006 ; 175 : 130-5.
Matousek RH, Sherwin BB. A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog. Psychoneuroendocrinology 2010 ; 35 : 215-25.
Sharma P, Wisniewski A, Braga-Basaria M, et al. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol 2009 ; 182 : 2265-72.
Barton DL, Burger K, Novotny PJ, et al. The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 2013 ; 21 : 1185-92.
Poppelreuter M, Weis J, Bartsch HH. Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J Psychosoc Oncol 2009 ; 27 : 274-96.
Von Ah D, Carpenter JS, Saykin A, et al. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 2012 ; 135 : 799-809.
Kesler SF, Hadi Hosseini SM, Heckler CF, et al. Cognitive training for improving executive function in chemotherapy-treated. Clin Breast Cancer 2013 ; 13 : 299-306.
Ferguson RJ, McDonald BC, Rocque MA, et al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology 2012 ; 21 : 176-86.
Schuurs A, Green HJ. A feasibility study of group cognitive rehabilitation for cancer survivors. Psychooncology 2013 ; 22 : 1043-9.
Cimprich B. Development of an intervention to restore attention in cancer patients. Cancer Nurs 1993 ; 16 : 83-92.
Cimprich B, Ronis DL. An environmental intervention to restore attention in women with newly diagnosed breast cancer. Cancer Nurs 2003 ; 26 : 284-92, quiz 293-4.
Oh B, Butow PN, Mullan BA, et al. Effect of medical Qigong on cognitive function, quality of life, and a biomarker. Support Care Cancer 2012 ; 20 : 1235-42.
Milbury K., Chaoul A., Biegler K., et al. Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology 2013 ; 22 : 2354-63.
Cherrier MM, Anderson K, David D, et al. A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci 2013 ; 93 : 617-22.
Correa DD, Rocco-Donovan M, DeAngelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 2009 ; 91 : 315-21.
Dubois M, Lapinte N, Villier V, et al. Chemotherapy-induced long-term alteration of executive functions and hippocampal cell proliferation: role of glucose as adjuvant. Neuropharmacology 2013 ; 79C : 234-48.
Gondi V, Tome WA, Mehta MP. Why avoid the hippocampus? A comprehensive review. Radiother Oncol 2010 ; 97 : 370-6.
Stern Y. Cognitive reserve. Neuropsychologia 2009 ; 47 : 2015-28.
Heflin LH, Meyerowitz BE, Hall P, et al. Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst 2005 ; 97 : 854-6.
Meyers CA, Perry JR. Cognition and cancer. Cambridge : Cambridge University Press ed, 2008, 356.
Butler RW, Mulhern RK. Neurocognitive interventions for children and adolescents surviving cancer. J Pediatr Psychol 2005 ; 30 : 65-78.
